HSG Blog

Research Round-Up

By: Lise Munsie, PhD In the lab. . . Future clinical treatments for HD are likely to vary from patient...

Lundbeck: Building Hope for HD with Casa De Hogar

Lundbeck: Building Hope for HD with Casa De Hogar

Lundbeck was pleased to donate a large supply of tetrabenazine to the Hereditary Disease Foundation to provide to the Casa...

Meet the Compound: Huntexil

  VITAL SIGNS NAME: Huntexil® (Pridopidine/ACR16) CHEMICAL FORMULA: C15H23NO2S MOLECULAR MASS: 281.41 g/mol. TYPE OF COMPOUND: Dopamine stabilizer MECHANISMS OF...

Meet the Investigator

VITAL SIGNS NAME: Michael Hayden, CM, OBC, MB, ChB, PhD, FRCP(C), FRSC CURRENT Dr. Michael Hayden was recently appointed as...

Meet the Company

              VITAL SIGNS NAME: Teva Pharmaceutical Industries, Ltd. HEADQUARTERS: Petah Tikva, Israel STOCK PRICE...

HD Insights Volume 6 (PDF)

HD Insights Volume 3 (PDF)

HSG Press Release: September 2012

2CARE (Coenzyme Q10 in Huntington’s Disease) Study Update September, 2012 Enrollment for the 2CARE study was closed on 25 July...

An Interview with Dr. Nancy Wexler: Discovering the Huntington Disease Gene

By: Kristin Darwin One morning in 1968, Dr. Nancy Wexler’s mother, Leonore Wexler, had jury duty in downtown Los Angeles....

Meet the Company

Meet the Company

        VITAL SIGNS NAME: Isis Pharmaceuticals HEADQUARTERS: Carlsbad, California STOCK PRICE AS OF 8/21/12: $13.67 52 WEEK...

1 18 19 20 21 22